Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

@article{Prinssen1998BiodistributionO1,
  title={Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01},
  author={Helma M. Prinssen and Carla F. M. Molthoff and Ren{\'e} H. M. Verheijen and Tim J. Broadhead and Peter Kenemans and J. D. Roos and Quentin Davies and Arjan C. van Hof and Malcolm E. Frier and Wim den Hollander and Abraham J. Wilhelm and Terry S. Baker and Mark Sopwith and Edwin Malcolm Symonds and Alan C. Perkins},
  journal={Cancer Immunology, Immunotherapy},
  year={1998},
  volume={47},
  pages={39-46}
}
mAb hCTM01 binds a carcinoma-associated antigen, the MUC1 gene product. The antigen is also present in the circulation, and administration of 111In-labelled hCTM01 results in the formation of immune complexes with enhanced accumulation in the liver. To avoid the unwanted effect of circulating radioactive immune complexes, a strategy to remove the circulating antigen was investigated using a split-dosage schedule. Eleven patients suspected of having ovarian carcinoma were injected with 1 mg/kg… CONTINUE READING
7 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Biodistribution of Indium-111 labeled engineered human antibody CTM01 in ovarian cancer patients: in ̄uence of protein dose

  • AC vanHof, CFM Moltho, +10 authors JC Roos
  • Cancer Res
  • 1996
Highly Influential
9 Excerpts

Imaging and radioimmunotargeting of ovarian cancer

  • M Buist, P Kenemans
  • Tumor Targets
  • 1995

Similar Papers

Loading similar papers…